One discovery engine. Several ways to earn from it.
Mahanim Biologics turns well-characterised patient cohorts into mechanism-level biomarker and target discoveries, then commercialises them through sponsored studies, licensing and co-developed products. This page sets out how the business works. Financials, market sizing and the full roadmap are in the investor deck.
Five customer groups, one platform underneath
Pharma & biotech
Sponsored discovery alongside a drug programme: mechanism and target leads, responder stratification and toxicity-risk work.
Hospitals & research institutes
Co-discovery and validation studies on their own cohorts, with jointly held IP that feeds the diagnostics pipeline.
Diagnostics companies
Validated signatures licensed into tests, so a partner with an existing route to market can build on them.
Probiotic & live-biotherapeutic companies
Strain nomination and engraftment analysis for candidate products, before they reach a trial.
Nutrition & performance companies
Personalised response signatures for diet and performance products.
See the applications
What each customer group actually gets, shown with a real finding for every use case.
The seven applications →Each study makes the next one worth more
A growing signature library
Every partner cohort adds India-specific signatures and mechanisms that the next study can start from.
IP at two levels
The platform itself, with patent filing in progress, and the findings from each study, held jointly with partners where agreed.
Discovery feeds products
Studies come first. The signatures that hold up become diagnostic panels, licensing assets and therapeutic leads.
The population that will use a test should be the one it is validated in
Most of the field's reference cohorts were built outside India. Diet, environment and medication shape the gut microbiome far more than host genetics does, so a signature built elsewhere has to be re-established here before it can guide care.
The groups that run those first Indian validation studies set the reference standard for everyone who follows. Mahanim Biologics is built to be the analytical partner in those studies, and to hold a stake in what they produce.
Company, IP and science in place
Varma S. Konala
Three decades building and commercialising advanced technology, including 24 years at Intel. Built and led INAI, the applied-AI institute set up by Intel India, IIIT Hyderabad and the Government of Telangana.
Jagriti Ramanathan
Computational biologist and inventor of MANTRA, with work across Imperial College London, the University of Edinburgh and AstraZeneca Cambridge. Author of 16 scientific publications.
Request the investor deck
Financials, market sizing and the full roadmap, shared on request.